Background Pituitary tumours are common and easily treated by surgery or medical
treatment in most cases. However, a small subset of pituitary tumours does not respond to …

Despite most of the prolactinomas can be treated with endocrine therapy and/or surgery, a
significant percentage of these tumors can be resistant to endocrine treatments and/or recur …

Context Aggressive prolactin (PRL)-secreting pituitary adenomas that are resistant to
conventional therapy with dopamine agonists, surgery, and radiation pose a therapeutic …

Abstract Pituitary tumors represent 10–15% of all intracranial tumors; of these, prolactinomas
account for 40–50% of cases. Prolactinomas usually respond well to dopamine agonists …

Aggressive pituitary tumors (APT) refer to pituitary adenomas exhibiting radiological
invasiveness and an unusually rapid tumor growth rate, or clinically relevant tumor growth …

Background Along with the presence of the 2011 Endocrine Society Clinical Practice
Guidelines and numerous large-scale studies on the treatment of hyperprolactinemia of …

Dopamine agonists (DAs, especially cabergoline) are recommended as first-line treatment
in patients with prolactin-secreting pituitary adenomas, to reduce hormone secretion and …

Pituitary adenomas (PA) are monoclonal tumors arising from the cells of the
adenohypophysis and represent approximately 10-15% of all intracranial tumors and 90% of …

The parenchyme of the anterior pituitary gland consists of various distinct endocrine cells
which second to the hypothalamic-releasing hormones regulates all other endocrine organs …

Background: Along with the presence of the 2011 Endocrine Society Clinical Practice
Guidelines and numerous large-scale studies on the treatment of hyperprolactinemia of …